RxSight, Inc. (RXST) Stock Competitors & Peer Comparison
See (RXST) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXST | $5.55 | -0.36% | 229.8M | -7.71 | -$0.72 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.68 | +1.87% | 175.3B | 19.32 | $5.21 | +2.48% |
| ISRG | $345.42 | -11.20% | 142.5B | 41.82 | $9.62 | N/A |
| SYK | $319.87 | -3.42% | 122.6B | 23.89 | $13.39 | +1.09% |
| MDT | $83.20 | -0.43% | 106.5B | 15.04 | $5.53 | +3.43% |
| BSX | $44.03 | -1.32% | 65.4B | 14.20 | $3.10 | N/A |
| EW | $85.73 | -2.40% | 49.4B | 31.75 | $2.70 | N/A |
| DXCM | $76.65 | -1.71% | 29.6B | 32.90 | $2.33 | N/A |
| RMD | $198.99 | -1.86% | 28.9B | 18.47 | $10.77 | +1.21% |
Stock Comparison
RXST vs BSX-PA Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RXST is priced at $5.55, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RXST's ROE is -0.17%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RXST is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BSX-PA's competition here
RXST vs ABT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, RXST is priced at $5.55, while ABT trades at $100.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ABT's P/E ratio is 19.32. In terms of profitability, RXST's ROE is -0.17%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RXST is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ABT's competition here
RXST vs ISRG Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, RXST is priced at $5.55, while ISRG trades at $345.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ISRG's P/E ratio is 41.82. In terms of profitability, RXST's ROE is -0.17%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RXST is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check ISRG's competition here
RXST vs SYK Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SYK has a market cap of 122.6B. Regarding current trading prices, RXST is priced at $5.55, while SYK trades at $319.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SYK's P/E ratio is 23.89. In terms of profitability, RXST's ROE is -0.17%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RXST is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SYK's competition here
RXST vs MDT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, MDT has a market cap of 106.5B. Regarding current trading prices, RXST is priced at $5.55, while MDT trades at $83.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas MDT's P/E ratio is 15.04. In terms of profitability, RXST's ROE is -0.17%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RXST is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check MDT's competition here
RXST vs BSX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BSX has a market cap of 65.4B. Regarding current trading prices, RXST is priced at $5.55, while BSX trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BSX's P/E ratio is 14.20. In terms of profitability, RXST's ROE is -0.17%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RXST is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BSX's competition here
RXST vs EW Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, RXST is priced at $5.55, while EW trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas EW's P/E ratio is 31.75. In terms of profitability, RXST's ROE is -0.17%, compared to EW's ROE of +0.11%. Regarding short-term risk, RXST is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check EW's competition here
RXST vs DXCM Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, RXST is priced at $5.55, while DXCM trades at $76.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas DXCM's P/E ratio is 32.90. In terms of profitability, RXST's ROE is -0.17%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RXST is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check DXCM's competition here
RXST vs RMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, RMD has a market cap of 28.9B. Regarding current trading prices, RXST is priced at $5.55, while RMD trades at $198.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas RMD's P/E ratio is 18.47. In terms of profitability, RXST's ROE is -0.17%, compared to RMD's ROE of +0.24%. Regarding short-term risk, RXST is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check RMD's competition here
RXST vs ZBH Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, RXST is priced at $5.55, while ZBH trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ZBH's P/E ratio is 10.75. In terms of profitability, RXST's ROE is -0.17%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RXST is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ZBH's competition here
RXST vs ABMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RXST is priced at $5.55, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RXST's ROE is -0.17%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RXST is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ABMD's competition here
RXST vs SNN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, RXST is priced at $5.55, while SNN trades at $30.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SNN's P/E ratio is 16.53. In terms of profitability, RXST's ROE is -0.17%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RXST is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SNN's competition here
RXST vs ALGN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ALGN has a market cap of 12.7B. Regarding current trading prices, RXST is priced at $5.55, while ALGN trades at $176.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ALGN's P/E ratio is 16.11. In terms of profitability, RXST's ROE is -0.17%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RXST is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ALGN's competition here
RXST vs SWAV Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RXST is priced at $5.55, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RXST's ROE is -0.17%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RXST is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SWAV's competition here
RXST vs PEN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, RXST is priced at $5.55, while PEN trades at $318.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PEN's P/E ratio is 83.11. In terms of profitability, RXST's ROE is -0.17%, compared to PEN's ROE of +0.12%. Regarding short-term risk, RXST is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check PEN's competition here
RXST vs PODD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PODD has a market cap of 11.4B. Regarding current trading prices, RXST is priced at $5.55, while PODD trades at $164.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PODD's P/E ratio is 30.49. In terms of profitability, RXST's ROE is -0.17%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RXST is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check PODD's competition here
RXST vs GMED Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, GMED has a market cap of 10.4B. Regarding current trading prices, RXST is priced at $5.55, while GMED trades at $77.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas GMED's P/E ratio is 17.34. In terms of profitability, RXST's ROE is -0.17%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RXST is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check GMED's competition here
RXST vs MASI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RXST is priced at $5.55, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas MASI's P/E ratio is 44.43. In terms of profitability, RXST's ROE is -0.17%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RXST is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check MASI's competition here
RXST vs GKOS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, GKOS has a market cap of 9.2B. Regarding current trading prices, RXST is priced at $5.55, while GKOS trades at $156.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas GKOS's P/E ratio is -182.44. In terms of profitability, RXST's ROE is -0.17%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RXST is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check GKOS's competition here
RXST vs BRKR Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, RXST is priced at $5.55, while BRKR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BRKR's P/E ratio is 31.99. In terms of profitability, RXST's ROE is -0.17%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RXST is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BRKR's competition here
RXST vs BIO-B Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BIO-B has a market cap of 8.4B. Regarding current trading prices, RXST is priced at $5.55, while BIO-B trades at $324.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BIO-B's P/E ratio is 96.41. In terms of profitability, RXST's ROE is -0.17%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RXST is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BIO-B's competition here
RXST vs BIO Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, RXST is priced at $5.55, while BIO trades at $304.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BIO's P/E ratio is 32.81. In terms of profitability, RXST's ROE is -0.17%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RXST is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BIO's competition here
RXST vs NARI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RXST is priced at $5.55, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas NARI's P/E ratio is -59.24. In terms of profitability, RXST's ROE is -0.17%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RXST is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check NARI's competition here
RXST vs LIVN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, RXST is priced at $5.55, while LIVN trades at $80.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas LIVN's P/E ratio is 20.18. In terms of profitability, RXST's ROE is -0.17%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RXST is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check LIVN's competition here
RXST vs IRTC Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, RXST is priced at $5.55, while IRTC trades at $110.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas IRTC's P/E ratio is -205.98. In terms of profitability, RXST's ROE is -0.17%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RXST is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check IRTC's competition here
RXST vs AXNX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RXST is priced at $5.55, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RXST's ROE is -0.17%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RXST is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check AXNX's competition here
RXST vs ITGR Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ITGR has a market cap of 3.4B. Regarding current trading prices, RXST is priced at $5.55, while ITGR trades at $95.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ITGR's P/E ratio is 15.81. In terms of profitability, RXST's ROE is -0.17%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RXST is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ITGR's competition here
RXST vs ESTA Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, RXST is priced at $5.55, while ESTA trades at $92.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ESTA's P/E ratio is -64.29. In terms of profitability, RXST's ROE is -0.17%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RXST is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ESTA's competition here
RXST vs TMDX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, RXST is priced at $5.55, while TMDX trades at $73.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas TMDX's P/E ratio is 30.20. In terms of profitability, RXST's ROE is -0.17%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RXST is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check TMDX's competition here
RXST vs AXGN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, RXST is priced at $5.55, while AXGN trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AXGN's P/E ratio is 104.87. In terms of profitability, RXST's ROE is -0.17%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RXST is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check AXGN's competition here
RXST vs NUVA Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RXST is priced at $5.55, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RXST's ROE is -0.17%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RXST is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check NUVA's competition here
RXST vs UFPT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, RXST is priced at $5.55, while UFPT trades at $242.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas UFPT's P/E ratio is 25.21. In terms of profitability, RXST's ROE is -0.17%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RXST is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check UFPT's competition here
RXST vs NVCR Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, RXST is priced at $5.55, while NVCR trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas NVCR's P/E ratio is -10.41. In terms of profitability, RXST's ROE is -0.17%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, RXST is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check NVCR's competition here
RXST vs BFLY Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, RXST is priced at $5.55, while BFLY trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BFLY's P/E ratio is -27.54. In terms of profitability, RXST's ROE is -0.17%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RXST is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check BFLY's competition here
RXST vs ENOV Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, RXST is priced at $5.55, while ENOV trades at $27.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ENOV's P/E ratio is 8.01. In terms of profitability, RXST's ROE is -0.17%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RXST is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check ENOV's competition here
RXST vs IART Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, RXST is priced at $5.55, while IART trades at $19.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas IART's P/E ratio is 8.41. In terms of profitability, RXST's ROE is -0.17%, compared to IART's ROE of -0.48%. Regarding short-term risk, RXST is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check IART's competition here
RXST vs AHCO Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, RXST is priced at $5.55, while AHCO trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AHCO's P/E ratio is 24.91. In terms of profitability, RXST's ROE is -0.17%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RXST is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check AHCO's competition here
RXST vs INSP Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, RXST is priced at $5.55, while INSP trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas INSP's P/E ratio is 19.97. In terms of profitability, RXST's ROE is -0.17%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RXST is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check INSP's competition here
RXST vs ATEC Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, RXST is priced at $5.55, while ATEC trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ATEC's P/E ratio is -77.59. In terms of profitability, RXST's ROE is -0.17%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RXST is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check ATEC's competition here
RXST vs HSKA Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RXST is priced at $5.55, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RXST's ROE is -0.17%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RXST is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check HSKA's competition here
RXST vs CNMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, RXST is priced at $5.55, while CNMD trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CNMD's P/E ratio is 9.51. In terms of profitability, RXST's ROE is -0.17%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RXST is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CNMD's competition here
RXST vs IRMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, RXST is priced at $5.55, while IRMD trades at $97.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas IRMD's P/E ratio is 49.13. In terms of profitability, RXST's ROE is -0.17%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RXST is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check IRMD's competition here
RXST vs AORT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, RXST is priced at $5.55, while AORT trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AORT's P/E ratio is 38.51. In terms of profitability, RXST's ROE is -0.17%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RXST is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check AORT's competition here
RXST vs TNDM Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, RXST is priced at $5.55, while TNDM trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas TNDM's P/E ratio is -15.53. In terms of profitability, RXST's ROE is -0.17%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RXST is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check TNDM's competition here
RXST vs AVNS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RXST is priced at $5.55, while AVNS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AVNS's P/E ratio is 27.76. In terms of profitability, RXST's ROE is -0.17%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RXST is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check AVNS's competition here
RXST vs SILK Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RXST is priced at $5.55, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SILK's P/E ratio is -18.96. In terms of profitability, RXST's ROE is -0.17%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RXST is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SILK's competition here
RXST vs FNA Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RXST is priced at $5.55, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas FNA's P/E ratio is -19.83. In terms of profitability, RXST's ROE is -0.17%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RXST is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check FNA's competition here
RXST vs PRCT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, RXST is priced at $5.55, while PRCT trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PRCT's P/E ratio is -10.56. In terms of profitability, RXST's ROE is -0.17%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RXST is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check PRCT's competition here
RXST vs LMRI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, RXST is priced at $5.55, while LMRI trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas LMRI's P/E ratio is -21.67. In terms of profitability, RXST's ROE is -0.17%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, RXST is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check LMRI's competition here
RXST vs INMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, INMD has a market cap of 896.4M. Regarding current trading prices, RXST is priced at $5.55, while INMD trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas INMD's P/E ratio is 10.00. In terms of profitability, RXST's ROE is -0.17%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RXST is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check INMD's competition here
RXST vs CSII Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RXST is priced at $5.55, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CSII's P/E ratio is -20.83. In terms of profitability, RXST's ROE is -0.17%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RXST is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CSII's competition here
RXST vs BVS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BVS has a market cap of 817M. Regarding current trading prices, RXST is priced at $5.55, while BVS trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BVS's P/E ratio is 16.08. In terms of profitability, RXST's ROE is -0.17%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RXST is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check BVS's competition here
RXST vs SIBN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SIBN has a market cap of 770.8M. Regarding current trading prices, RXST is priced at $5.55, while SIBN trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SIBN's P/E ratio is -44.56. In terms of profitability, RXST's ROE is -0.17%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RXST is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SIBN's competition here
RXST vs SSII Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SSII has a market cap of 742.5M. Regarding current trading prices, RXST is priced at $5.55, while SSII trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SSII's P/E ratio is -72.36. In terms of profitability, RXST's ROE is -0.17%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RXST is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SSII's competition here
RXST vs CBLL Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CBLL has a market cap of 710.3M. Regarding current trading prices, RXST is priced at $5.55, while CBLL trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CBLL's P/E ratio is -11.48. In terms of profitability, RXST's ROE is -0.17%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RXST is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CBLL's competition here
RXST vs TCMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, TCMD has a market cap of 648.3M. Regarding current trading prices, RXST is priced at $5.55, while TCMD trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas TCMD's P/E ratio is 32.66. In terms of profitability, RXST's ROE is -0.17%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RXST is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check TCMD's competition here
RXST vs CERS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CERS has a market cap of 627.2M. Regarding current trading prices, RXST is priced at $5.55, while CERS trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CERS's P/E ratio is -62.48. In terms of profitability, RXST's ROE is -0.17%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RXST is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check CERS's competition here
RXST vs BWAY Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BWAY has a market cap of 617M. Regarding current trading prices, RXST is priced at $5.55, while BWAY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BWAY's P/E ratio is 39.96. In terms of profitability, RXST's ROE is -0.17%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, RXST is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check BWAY's competition here
RXST vs SRDX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RXST is priced at $5.55, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RXST's ROE is -0.17%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, RXST is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SRDX's competition here
RXST vs CTKB Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CTKB has a market cap of 596.6M. Regarding current trading prices, RXST is priced at $5.55, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CTKB's P/E ratio is -35.54. In terms of profitability, RXST's ROE is -0.17%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RXST is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CTKB's competition here
RXST vs APEN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RXST is priced at $5.55, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas APEN's P/E ratio is -9.43. In terms of profitability, RXST's ROE is -0.17%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RXST is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check APEN's competition here
RXST vs NPCE Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, NPCE has a market cap of 548.2M. Regarding current trading prices, RXST is priced at $5.55, while NPCE trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas NPCE's P/E ratio is -27.72. In terms of profitability, RXST's ROE is -0.17%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RXST is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check NPCE's competition here
RXST vs ZIMV Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RXST is priced at $5.55, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RXST's ROE is -0.17%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, RXST is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ZIMV's competition here
RXST vs KIDS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, KIDS has a market cap of 493.5M. Regarding current trading prices, RXST is priced at $5.55, while KIDS trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas KIDS's P/E ratio is -18.66. In terms of profitability, RXST's ROE is -0.17%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RXST is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check KIDS's competition here
RXST vs OFIX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, OFIX has a market cap of 468.1M. Regarding current trading prices, RXST is priced at $5.55, while OFIX trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas OFIX's P/E ratio is -47.17. In terms of profitability, RXST's ROE is -0.17%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RXST is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check OFIX's competition here
RXST vs CLPT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CLPT has a market cap of 454.3M. Regarding current trading prices, RXST is priced at $5.55, while CLPT trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CLPT's P/E ratio is -15.00. In terms of profitability, RXST's ROE is -0.17%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RXST is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CLPT's competition here
RXST vs PACB Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PACB has a market cap of 447.3M. Regarding current trading prices, RXST is priced at $5.55, while PACB trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PACB's P/E ratio is -2.94. In terms of profitability, RXST's ROE is -0.17%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RXST is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check PACB's competition here
RXST vs VREX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, VREX has a market cap of 444.2M. Regarding current trading prices, RXST is priced at $5.55, while VREX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas VREX's P/E ratio is 11.11. In terms of profitability, RXST's ROE is -0.17%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RXST is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check VREX's competition here
RXST vs DCTH Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, DCTH has a market cap of 442.2M. Regarding current trading prices, RXST is priced at $5.55, while DCTH trades at $12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas DCTH's P/E ratio is 1281.00. In terms of profitability, RXST's ROE is -0.17%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RXST is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check DCTH's competition here
RXST vs ELMD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ELMD has a market cap of 348.8M. Regarding current trading prices, RXST is priced at $5.55, while ELMD trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ELMD's P/E ratio is 36.00. In terms of profitability, RXST's ROE is -0.17%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RXST is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ELMD's competition here
RXST vs CARL Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CARL has a market cap of 317M. Regarding current trading prices, RXST is priced at $5.55, while CARL trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CARL's P/E ratio is -4.65. In terms of profitability, RXST's ROE is -0.17%, compared to CARL's ROE of -0.62%. Regarding short-term risk, RXST is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CARL's competition here
RXST vs AVR Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, AVR has a market cap of 310.9M. Regarding current trading prices, RXST is priced at $5.55, while AVR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas AVR's P/E ratio is -3.79. In terms of profitability, RXST's ROE is -0.17%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RXST is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check AVR's competition here
RXST vs SMLR Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RXST is priced at $5.55, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RXST's ROE is -0.17%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, RXST is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SMLR's competition here
RXST vs TMCI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, TMCI has a market cap of 279M. Regarding current trading prices, RXST is priced at $5.55, while TMCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas TMCI's P/E ratio is -4.57. In terms of profitability, RXST's ROE is -0.17%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RXST is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check TMCI's competition here
RXST vs SGHT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, RXST is priced at $5.55, while SGHT trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SGHT's P/E ratio is -7.08. In terms of profitability, RXST's ROE is -0.17%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RXST is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SGHT's competition here
RXST vs MGRM Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RXST is priced at $5.55, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas MGRM's P/E ratio is -12.00. In terms of profitability, RXST's ROE is -0.17%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, RXST is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check MGRM's competition here
RXST vs CATX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CATX has a market cap of 230.7M. Regarding current trading prices, RXST is priced at $5.55, while CATX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CATX's P/E ratio is -2.12. In terms of profitability, RXST's ROE is -0.17%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RXST is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check CATX's competition here
RXST vs NVRO Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RXST is priced at $5.55, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RXST's ROE is -0.17%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RXST is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check NVRO's competition here
RXST vs PMI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PMI has a market cap of 220.4M. Regarding current trading prices, RXST is priced at $5.55, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PMI's P/E ratio is -0.12. In terms of profitability, RXST's ROE is -0.17%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RXST is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check PMI's competition here
RXST vs SENS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, SENS has a market cap of 213.6M. Regarding current trading prices, RXST is priced at $5.55, while SENS trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas SENS's P/E ratio is -2.56. In terms of profitability, RXST's ROE is -0.17%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RXST is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check SENS's competition here
RXST vs PROF Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, PROF has a market cap of 207.3M. Regarding current trading prices, RXST is priced at $5.55, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas PROF's P/E ratio is -5.52. In terms of profitability, RXST's ROE is -0.17%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RXST is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check PROF's competition here
RXST vs FOCL Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, FOCL has a market cap of 203.7M. Regarding current trading prices, RXST is priced at $5.55, while FOCL trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas FOCL's P/E ratio is -6.99. In terms of profitability, RXST's ROE is -0.17%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, RXST is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check FOCL's competition here
RXST vs ANIK Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ANIK has a market cap of 202.9M. Regarding current trading prices, RXST is priced at $5.55, while ANIK trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ANIK's P/E ratio is 31.12. In terms of profitability, RXST's ROE is -0.17%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RXST is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ANIK's competition here
RXST vs BSGM Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RXST is priced at $5.55, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RXST's ROE is -0.17%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, RXST is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check BSGM's competition here
RXST vs QTRX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, QTRX has a market cap of 182.1M. Regarding current trading prices, RXST is priced at $5.55, while QTRX trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas QTRX's P/E ratio is -2.42. In terms of profitability, RXST's ROE is -0.17%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RXST is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check QTRX's competition here
RXST vs INGN Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, INGN has a market cap of 180.3M. Regarding current trading prices, RXST is priced at $5.55, while INGN trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas INGN's P/E ratio is -7.32. In terms of profitability, RXST's ROE is -0.17%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RXST is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check INGN's competition here
RXST vs MDGS Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RXST is priced at $5.55, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RXST's ROE is -0.17%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RXST is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check MDGS's competition here
RXST vs TLSI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, TLSI has a market cap of 162.6M. Regarding current trading prices, RXST is priced at $5.55, while TLSI trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas TLSI's P/E ratio is -2.55. In terms of profitability, RXST's ROE is -0.17%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, RXST is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check TLSI's competition here
RXST vs QIPT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RXST is priced at $5.55, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RXST's ROE is -0.17%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RXST is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check QIPT's competition here
RXST vs CVRX Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, CVRX has a market cap of 130.3M. Regarding current trading prices, RXST is priced at $5.55, while CVRX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas CVRX's P/E ratio is -2.43. In terms of profitability, RXST's ROE is -0.17%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RXST is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check CVRX's competition here
RXST vs RCEL Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, RCEL has a market cap of 126.7M. Regarding current trading prices, RXST is priced at $5.55, while RCEL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas RCEL's P/E ratio is -3.25. In terms of profitability, RXST's ROE is -0.17%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, RXST is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check RCEL's competition here
RXST vs ICAD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RXST is priced at $5.55, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RXST's ROE is -0.17%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, RXST is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ICAD's competition here
RXST vs OWLT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, OWLT has a market cap of 101.1M. Regarding current trading prices, RXST is priced at $5.55, while OWLT trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas OWLT's P/E ratio is -39.93. In terms of profitability, RXST's ROE is -0.17%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, RXST is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check OWLT's competition here
RXST vs HSDT Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, HSDT has a market cap of 99.8M. Regarding current trading prices, RXST is priced at $5.55, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas HSDT's P/E ratio is -0.02. In terms of profitability, RXST's ROE is -0.17%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, RXST is more volatile compared to HSDT. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check HSDT's competition here
RXST vs HJLI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, RXST is priced at $5.55, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas HJLI's P/E ratio is N/A. In terms of profitability, RXST's ROE is -0.17%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, RXST is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check HJLI's competition here
RXST vs LUCD Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, LUCD has a market cap of 97.2M. Regarding current trading prices, RXST is priced at $5.55, while LUCD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas LUCD's P/E ratio is -2.57. In terms of profitability, RXST's ROE is -0.17%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, RXST is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check LUCD's competition here
RXST vs ASXC Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, RXST is priced at $5.55, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas ASXC's P/E ratio is -1.12. In terms of profitability, RXST's ROE is -0.17%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, RXST is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check ASXC's competition here
RXST vs RPID Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, RPID has a market cap of 93.8M. Regarding current trading prices, RXST is priced at $5.55, while RPID trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas RPID's P/E ratio is -1.85. In terms of profitability, RXST's ROE is -0.17%, compared to RPID's ROE of -1.32%. Regarding short-term risk, RXST is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for RXST.Check RPID's competition here
RXST vs QTI Comparison July 2026
RXST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXST stands at 229.8M. In comparison, QTI has a market cap of 89M. Regarding current trading prices, RXST is priced at $5.55, while QTI trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXST currently has a P/E ratio of -7.71, whereas QTI's P/E ratio is -4.82. In terms of profitability, RXST's ROE is -0.17%, compared to QTI's ROE of -63.31%. Regarding short-term risk, RXST is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for RXST.Check QTI's competition here